The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.
Astellas Pharma, a pharmaceutical company headquartered in Japan, announced on Jan. 13, 2019 that it is entering into a co-development and co-commercialization agreement for cell therapies with United Kingdom-based Adaptimmune Therapeutics in a deal worth potentially up to $897.5 million.
Under the agreement, Adaptimmune may receive up to $897.5 million in payments, including an upfront payment of $50 million, development milestones totaling up to $73.75 million for each co-developed, co-commercialized product, and research funding of $7.5 million per year, according to an Astellas press release. In turn, Astellas will receive up to $147.5 million in milestone payments per product and up to $110 million in sales milestones for products developed unilaterally by Adaptimmune. Both companies will also obtain tiered royalties on net sales in the mid-single to mid-teen digits.
The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer. The companies will choose up to three targets around which to develop their T-cell candidates, and Astellas will fund research up until completion of a Phase I trial for each candidate. After Phase I is complete, the companies will decide to proceed with co-development and commercialization or to allow one of the companies to proceed with the candidate independently through a milestone and royalty bearing license, with the agreement allowing for either company to opt out.
"In addition to NK [natural killer] cells, T-cells are an important component of cell therapy for immuno-oncology, and we look forward that this agreement with Adaptimmune will enable us to create new stem-cell derived allogeneic T-cell therapies for a variety of cancers, including solid tumors, in the future,” said Naoki Okamura, representative director corporate executive vice-president, chief strategy officer, and chief financial officer, Astellas, in the press release. “We will continue to dedicate our efforts in delivering novel treatments for diseases with high unmet medical needs, pursuing cutting-edge science and technological advances.”
“We are delighted to establish this significant co-development partnership with Astellas, which builds upon and substantially extends an existing collaboration focused on gene editing of iPSC [induced pluripotent stem cells],” added Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, in the press release. “This new collaboration may encompass both CAR-T [chimeric antigen receptor T cell] and TCR [T-cell receptor] T-cell approaches, including our novel HLA [human leukocyte antigen]-independent TCR platform. It brings together highly complementary skills and expertise across the two organizations, and will enable the accelerated development of new, off-the-shelf T-cell therapy products for people with cancer.”
Source: Astellas
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.